A Study to Evaluate Safety and Efficacy of Bomedemstat (MK-3543-017)

NCT06351631 · clinicaltrials.gov ↗

PHASE3

Phase

RECRUITING

Status

400

Enrollment

INDUSTRY

Sponsor class

Conditions

Thrombocythemia, Essential
Primary Myelofibrosis
Myelofibrosis
Post-polycythemia Vera Myelofibrosis
Post-essential Thrombocythemia Myelofibrosis
Polycythemia Vera

Interventions

DRUG: Bomedemstat

Sponsor

Merck Sharp & Dohme LLC